The role of cell-free DNA in predicting colorectal cancer prognosis

References

• El-Shami K, Oeffinger KC, Erb NL, et al. American cancer society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65(6):427–455.
   Web of Science ®Google Scholar
• Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int. 2015;2015. DOI:10.1155/2015/149014):1-14
   PubMedGoogle Scholar
• Linnekamp JF, Wang X, Medema JP, et al. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 2015;75(2):245–249.
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Lange A, Prenzler A, et al. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19(11):1156–1168.
   PubMed Web of Science ®Google Scholar
• Woo J, Palmisiano N, Tester W, et al. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer. 2013;119(11):1941–1950.
   PubMed Web of Science ®Google Scholar
• Park T, Choi C, Choi Y, et al. Cost-effectiveness of cetuximab for colorectal cancer. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):667–677.
   PubMed Web of Science ®Google Scholar
• Troiani T, Zappavigna S, Martinelli E, et al. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther. 2013;13(2):241–255.
   PubMed Web of Science ®Google Scholar
• Lianidou ES. Circulating tumor cell isolation: a marathon race worth running. Clin Chem. 2014;60(2):287–289.
   PubMed Web of Science ®Google Scholar
• Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015;33(12):1348–1355.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Liu XQ, Fan Y, et al. Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer. Future Oncol. 2016;12(6):789–799.
   PubMed Web of Science ®Google Scholar
• Schramm A, Friedl TW, Schochter F, et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2016;293(2):271–281.
   PubMed Web of Science ®Google Scholar
• Lyberopoulou A, Galanopoulos M, Aravantinos G, et al. Identification of methylation profiles of cancer-related genes in circulating tumor cells population. Anticancer Res. 2017;3(37):1105–1112.
   Google Scholar
• Qin Z, Ljubimov VA, Zhou C, et al. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35:36.
   PubMed Web of Science ®Google Scholar
• Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. CR Seances Soc Biol Fil. 1948;3–4(142):241–243.
   Google Scholar
• Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–12.
   PubMed Web of Science ®Google Scholar
• Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313(1–2):139–142.
   PubMed Web of Science ®Google Scholar
• Giacona MB, Ruben GC, Iczkowski KA, et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17(1):89–97.
   PubMed Web of Science ®Google Scholar
• Francis G, Stein S. Circulating cell-free tumour DNA in the management of cancer. Int J Mol Sci. 2015;16(6):14122–14142.
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res. 2015;21(21):4786–4800.
   PubMed Web of Science ®Google Scholar
• Galanopoulos M, Papanikolaou IS, Zografos E, et al. Comparative study of mutations in single nucleotide polymorphism loci of KRAS and BRAF genes in patients who underwent screening colonoscopy, with and without premalignant intestinal polyps. Anticancer Res. 2017;2(37):651–657.
   Google Scholar
• Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459–465.
   PubMed Web of Science ®Google Scholar
• Kleist B, Kempa M, Meurer T, et al. Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. J Clin Pathol. 2016;69(3):204–208.
   PubMed Web of Science ®Google Scholar
• Amankwatia EB, Chakravarty P, Carey FA, et al. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 2015;112(9):1480–1490.
   PubMed Web of Science ®Google Scholar
• Choi YW, Song YS, Lee H, et al. MicroRNA expression signatures associated with BRAF-mutated versus KRAS-mutated colorectal cancers. Medicine. 2016;95(15):e3321.
   PubMed Web of Science ®Google Scholar
• Cisowski J, Sayin VI, Liu M, et al. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Oncogene. 2016;35(10):1328–1333.
   PubMed Web of Science ®Google Scholar
• Eng C, Bessudo A, Hart LL, et al. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer. 2016;139(1):177–186.
   PubMed Web of Science ®Google Scholar
• Spindler KG, Appelt AL, Pallisgaard N, et al. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer. 2013;109(12):3067–3072.
   PubMed Web of Science ®Google Scholar
• Waring P, Tie J, Maru D. RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer. Clin Colorectal Cancer. 2016;2(15):95–103.
   Google Scholar
• Malapelle U, Bellevicine C, Salatiello M, et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist’s perspective. J Clin Pathol. 2012;65(10):940–944.
   PubMed Web of Science ®Google Scholar
• Yamada T, Iwai T, Takahashi G, et al. Utility of KRAS mutation detection using circulating cell‐free DNA from patients with colorectal cancer. Cancer Sci. 2016;107(7):936–943.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Pallisgaard N, Appelt AL, et al. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. Eur J Cancer. 2015;51(17):2678–2685.
   PubMed Web of Science ®Google Scholar
• Shitara K, Yonesaka K, Denda T, et al. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G. Cancer Sci. 2016;107(12):1843–1850.
   PubMed Web of Science ®Google Scholar
• Janowski E, Timofeeva O, Chasovskikh S, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: clinical and ccfDNA studies. Oncol Rep. 2017;37:57–65.
   PubMed Web of Science ®Google Scholar
• Kuo YB, Chen JS, Fan CW, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–289.
   PubMed Web of Science ®Google Scholar
• Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage iii colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890–900.
   PubMed Web of Science ®Google Scholar
• Maughan TS, Meade AM, Adams RA, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer. 2014;110(9):2178.
   PubMed Web of Science ®Google Scholar
• Spindler KG, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer: results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014;135(9):2215–2222.
   PubMed Web of Science ®Google Scholar
• Mouliere F, El Messaoudi S, Gongora C, et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol. 2013;6(3):319–IN8.
   PubMed Web of Science ®Google Scholar
• Spindler KLG, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18(4):1177–1185.
   PubMed Web of Science ®Google Scholar
• Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Biochim Biophys Acta. 2004;4(9):707–717.
   Google Scholar
• Liu Y, Chew MH, Tham CK, et al. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am J Cancer Res. 2016;9(6):2098–2108.
   Google Scholar
• Matthaios D, Balgkouranidou I, Karaylannais A, et al. Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol Lett. 2016;12:748–759.
   PubMed Web of Science ®Google Scholar
• Philipp AB, Nagel D, Stieber P, et al. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer. 2014;14:245.
   PubMed Web of Science ®Google Scholar
• Tóth K, Wasserkort R, Sipos F, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA: e115415. PLoS One. 2014;9(12):e115415.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Sunami E, Tanaka T, et al. Incidence and prognostic significance of positive peritoneal lavage in colorectal cancer. Surg Today. 2015;45(9):1073–1081.
   PubMed Web of Science ®Google Scholar
• Kamiyama H, Noda H, Takata O, et al. Promoter hypermethylation of tumor-related genes in peritoneal lavage and the prognosis of patients with colorectal cancer. J Surg Oncol. 2009;100(1):69–74.
   PubMed Web of Science ®Google Scholar
• Lu F, Du G, Zheng S, et al. Detection of CDH1 gene methylation of suspension cells in abdominal lavage fluid from colorectal cancer patients and its clinical significance. Chin J Gastr Surg. 2014;17(11):1133.
   Google Scholar
• Rodic N, Burns KH. Long interspersed element-1 (LINE-1): passenger or driver in human neoplasms? PLoS Genet. 2013;9(3):e1003402.
   PubMed Web of Science ®Google Scholar
• Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32(3):e38.
   PubMed Web of Science ®Google Scholar
• Lou YT, Chen CW, Fan YC, et al. LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy. PLoS One. 2014;10(4):e0123973.
   PubMed Web of Science ®Google Scholar
• Kaneko M, Kotake M, Bando H, et al. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. BMC Cancer. 2016;16(1):945.
   PubMedGoogle Scholar
• Inamura K, Yamauchi M, Nishihara R, et al. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst. 2014;9(106):dju195.
   Google Scholar
• Zhuo C, Li Z, Xu Y, et al. Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival. Mol Cancer. 2014;13:153.
   PubMed Web of Science ®Google Scholar
• Moutinho C, Martinez-Cardús A, Santos C, et al. Epigenetic Inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J Natl Cancer Inst. 2014;1(106):djt322.
   Google Scholar
• Jiang G, Luo C, Sun M, et al. Methylation of CDX2 as a predictor in poor clinical outcome of patients with colorectal cancer. Genet Test Mol Biomarkers. 2016;20(11):710–714.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang G, He B, et al. Methylation of the UNC5C gene and its protein expression in colorectal cancer. Tumour Biol. 2017;39(4):1010428317697564.
   Web of Science ®Google Scholar
• Draht MX, Smits KM, Tournier B, et al. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. Mol Oncol. 2014;8(3):679–688.
   PubMed Web of Science ®Google Scholar
• Rasmussen SL, Krarup HB, Sunesen KG, et al. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal Dis. 2016;18(6):549–561.
   PubMed Web of Science ®Google Scholar
• Veganzones S, Maestro ML, Rafael S, et al. Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. Tumour Biol. 2015;36(5):3853–3861.
   PubMed Web of Science ®Google Scholar
• Barault L, Amatu A, Bleeker FE, et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015;26(9):1994–1999.
   PubMed Web of Science ®Google Scholar
• Oliver JA, Ortiz R, Melguizo C, et al. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer. 2014;14(1):511.
   PubMedGoogle Scholar
• Tsai M, Chen W, Yu S, et al. DNA hypermethylation of SHISA3 in colorectal cancer: an independent predictor of poor prognosis. Ann Surg Oncol. 2015;22(S3):1481–1489.
   Google Scholar
• Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer. 2011;104(11):1786–1790.
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen H, Huo L, et al. Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer. Mol Cancer Res. 2015;13(1):107–119.
   PubMed Web of Science ®Google Scholar
• Symonds EL, Pedersen SK, Baker RT, et al. A blood test for methylated BCAT1 and IKZF1 vs. a fecal immunochemical test for detection of colorectal neoplasia. Clin Transl Gastroenterol. 2016;7(1):e137.
   PubMed Web of Science ®Google Scholar
• Moya P, Esteban S, Fernandez-Suarez A, et al. KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumour Biol. 2013;34(1):471–479.
   PubMed Web of Science ®Google Scholar
• He T, Zhang M, Zheng R, et al. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer. Epigenomics. 2017;9(6):849–862.
   PubMed Web of Science ®Google Scholar
• Pfütze K, Benner A, Hoffmeister M, et al. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics. 2015;106(6):348–354.
   PubMed Web of Science ®Google Scholar
• Veganzones-De-Castro S, Rafael-Fernandez S, Vidaurreta-Lazaro M, et al. p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev Esp Enferm Dig. 2012;104(3):111–117.
   PubMed Web of Science ®Google Scholar
• Wettergren Y, Odin E, Nilsson S, et al. p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol Med. 2008;14(7–8):412.
   PubMed Web of Science ®Google Scholar
• Jiang G, Lin J, Wang W, et al. WNT5A promoter methylation is associated with better responses and longer progression-free survival in colorectal cancer patients treated with 5-fluorouracil-based chemotherapy. Genet Test Mol Biomarkers. 2017;21(2):74–79.
   PubMed Web of Science ®Google Scholar
• Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci. 2015;2:13.
   PubMed Web of Science ®Google Scholar
• Galanopoulos M, Tsoukalas N, Papanikolaou IS, et al. Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: a review of literature. World J Gastrointest Oncol. 2017;9(4):142.
   PubMed Web of Science ®Google Scholar
• Beránek M, Sirák M, Vošmik I, et al. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer. Acta Medica (Hradec Kralove, Czech Republic). 2016;59(2):54–58.
   PubMedGoogle Scholar
• Bedin C, Enzo MV, Del BP, et al. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer. 2017;140(8):1888–1898.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Appelt AL, Pallisgaard N, et al. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 2014;135(12):2984–2991.
   PubMed Web of Science ®Google Scholar
• Czeiger D, Shaked G, Sebbag G, et al. Elevated cell-free DNA measured by a simple assay is associated with increased rate of colorectal cancer relapse. Am J Clin Pathol. 2016;145(6):852–857.
   PubMed Web of Science ®Google Scholar
• Basnet S, Zhang ZY, Liao WQ, et al. The prognostic value of circulating cell-free DNA in colorectal cancer: a meta-analysis. J Cancer. 2016;7(9):1105–1113.
   PubMed Web of Science ®Google Scholar
• Stein U, Burock S, Herrmann P, et al. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLOS One. 2012;11(7):e49249.
   Google Scholar
• Zhang X, Yang X, Zhang Y, et al. Direct serum assay for cell-free Bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer. Clin Cancer Res. 2015;21(5):1225–1233.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhai B, Fang T, et al. FXR1 is elevated in colorectal cancer and acts as an oncogene. Tumour Biol. 2016;37(2):2683–2690.
   PubMed Web of Science ®Google Scholar
• Wong SC, Lo SF, Cheung MT, et al. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 2004;10(5):1613–1617.
   PubMed Web of Science ®Google Scholar
• Lledo S, Garcia-Granero E, Dasi F, et al. Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis Off J Assoc Coloproctol Great Britain Ireland. 2004;6(4):236–242.
   PubMedGoogle Scholar
• Garcia V, Garcia JM, Pena C, et al. Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res. 2006;12(7 Pt 1):2095–2100.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Guo X, et al. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer. Tumour Biol. 2016;37(7):8765–8773.
   PubMed Web of Science ®Google Scholar
• Jinushi T, Shibayama Y, Kinoshita I, et al. Low expression levels of microRNA‐124‐5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 2014;3(6):1544–1552.
   PubMed Web of Science ®Google Scholar
• Yuan D, Li K, Zhu K, et al. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol Ther. 2015;16(2):268–275.
   PubMed Web of Science ®Google Scholar
• Kjersem JB, Ikdahl T, Lingjaerde OC, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014;8(1):59–67.
   PubMed Web of Science ®Google Scholar
• Hansen TF, Carlsen AL, Heegaard NH, et al. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015;112(4):624–629.
   PubMed Web of Science ®Google Scholar
• Kijima T, Hazama S, Tsunedomi R, et al. MicroRNA-6826 and -6875 in plasma are valuable noninvasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncol Rep. 2017;37(1):23–30.
   PubMed Web of Science ®Google Scholar
• Azizian A, Kramer F, Jo P, et al. Preoperative prediction of lymph node status by circulating Mir-18b and Mir-20a during chemoradiotherapy in patients with rectal cancer. World J Surg. 2015;39(9):2329–2335.
   PubMed Web of Science ®Google Scholar
• Hu J, Cai G, Xu Y, et al. The plasma microRNA miR-1914* and −1915 suppresses chemoresistant in colorectal cancer patients by down-regulating NFIX. Curr Mol Med. 2016;16(1):70–82.
   PubMed Web of Science ®Google Scholar
• Wang S, Xiang J, Li Z, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2015;136(1):152–161.
   PubMed Web of Science ®Google Scholar
• Zheng G, Du L, Yang X, et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer. 2014;111(10):1985–1992.
   PubMed Web of Science ®Google Scholar
• Chambers JA, Callander AS, Grangeret R, et al. Attitudes towards the faecal occult blood test (FOBT) versus the faecal immunochemical test (FIT) for colorectal cancer screening: perceived ease of completion and disgust. BMC Cancer. 2016;16:96.
   Web of Science ®Google Scholar
• Hassan C, Giorgi RP, Camilloni L, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther. 2012;36(10):929–940.
   PubMed Web of Science ®Google Scholar
• Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci. 2015;60(3):609–622.
   PubMed Web of Science ®Google Scholar
• Malik P. A novel multitarget stool DNA test for colorectal cancer screening. Postgrad Med. 2016;128(2):268–272.
   PubMed Web of Science ®Google Scholar
• Zhang H, Song Y, Dang C. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 2013;10(3):230–234.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Guo Q, et al. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. Dis Markers. 2015;2015:1–6.
   Google Scholar
• Kisiel JB, Yab TC, Taylor WR, et al. Stool methylated DNA markers decrease following colorectal cancer resection—implications for surveillance. Dig Dis Sci. 2014;59(8):1764–1767.
   PubMed Web of Science ®Google Scholar
• Mansour H. Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection. Front Genet. 2014;5:182.
   PubMed Web of Science ®Google Scholar
• Perez-Santiago J, Schrier RD, de Oliveira MF, et al. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. J Neurovirol. 2016;22(2):191–200.
   PubMed Web of Science ®Google Scholar
• Pérez-Santiago J, Schrier RD, de Oliveira MF, et al. Cell-free total and fetal DNA in first trimester maternal serum and subsequent development of preeclampsia. J Neurovirol. 2016;2(22):191–200.
   Google Scholar
• Rodrigues Filho EM, Simon D, Ikuta N, et al. Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury. J Neurotrauma. 2014;31(19):1639–1646.
   PubMed Web of Science ®Google Scholar
• Toth K, Patai AV, Kalmar A, et al. Circadian rhythm of methylated septin 9, cell-free DNA amount and tumor markers in colorectal cancer patients. Pathol Oncol Res. 2016. DOI:10.1007/s12253-016-0174-2
   Web of Science ®Google Scholar
• Weijenberg MP, Lüchtenborg M, de Goeij AFPM, et al. Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. Cancer Causes Control. 2007;18(8):865–879.
   PubMed Web of Science ®Google Scholar
• Shuai Z, Yijun C, Zhanmeng Z, et al. Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: a comparison with colon and rectal cancers. Mol Clin Oncol. 2013;1:1072–1078.
   PubMedGoogle Scholar
• Zhi-Zhou S, Yue-Ming Z, Li S, et al. Genomic profiling of rectal adenoma and carcinoma by array-based comparative genomic hybridization. BMC Med Genomics. 2012;16(5):52.
   Google Scholar
• Wong AL, Lim JS, Sinha A, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015;13(1):57.
   PubMedGoogle Scholar
• Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007;25(24):3712–3718.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Pallisgaard N, Andersen RF, et al. Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. Anticancer Res. 2014;34(2):845–850.
   PubMed Web of Science ®Google Scholar
• Avallone A, Piccirillo MC, Aloj L, et al. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). BMC Cancer. 2016;16(1):69.
   PubMedGoogle Scholar
• Kim ST, Lee WS, Lanman RB, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget. 2015;6(37):40360–40369.
   PubMed Web of Science ®Google Scholar